Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients. The trial has recruited 104 patients in 12 hospitals in Spain. The primary endpoint of...